Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.
Ontology highlight
ABSTRACT: Heterologous polyclonal antibodies (pAb) were shown to possess oncolytic properties a century ago with reported clinical responses. More recent preclinical models confirmed pAb efficacy, though their ability to tackle complex target antigens reduces susceptibility to tumor escape. Owing to the recent availability of glyco-humanized pAb (GH-pAb) with acceptable clinical toxicology profile, we revisited use of pAb in oncology and highlighted their therapeutic potential against multiple cancer types. Murine antitumor pAb were generated after repeated immunization of rabbits with murine tumor cell lines from hepatocarcinoma, melanoma, and colorectal cancers. Antitumor pAb recognized and showed cytotoxicity against their targets without cross-reactivity with healthy tissues. In vivo, pAb are ef
SUBMITTER: Ciron C
PROVIDER: S-EPMC10967460 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA